Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/6/2024 | $8.00 | Buy | Craig Hallum |
| 2/28/2022 | $26.00 → $25.00 | Buy | HC Wainwright & Co. |
| 1/5/2022 | Outperform | William Blair | |
| 12/8/2021 | $19.00 | Outperform | Robert W. Baird |
| 12/8/2021 | $19.00 | Outperform | Baird |
| 8/10/2021 | $25.00 → $26.00 | Buy | HC Wainwright & Co. |
| 8/9/2021 | $30.00 → $20.00 | Buy | Maxim Group |
8-K - Cardiff Oncology, Inc. (0001213037) (Filer)
10-Q - Cardiff Oncology, Inc. (0001213037) (Filer)
8-K - Cardiff Oncology, Inc. (0001213037) (Filer)
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Cardiff Oncology (NASDAQ:CRDF) with a Buy and maintains $14 price target.
Gainers Helius Medical Tech (NASDAQ:HSDT) shares increased by 48.9% to $3.96 during Friday's pre-market session. The company's market cap stands at $3.5 million. Vaxxinity (NASDAQ:VAXX) shares moved upwards by 41.17% to $0.15. The company's market cap stands at $18.6 million. Jaguar Health (NASDAQ:JAGX) shares moved upwards by 28.37% to $0.38. The market value of their outstanding shares is at $108.1 million. Healthcare Triangle (NASDAQ:HCTI) shares moved upwards by 19.56% to $1.47. The company's market cap stands at $6.8 million. Ardelyx (NASDAQ:ARDX) stock increased by 16.64% to $7.92. The company's market cap stands at $1.8 billion. As per the news, the Q1 earnings report came out ye
- Protects the use of onvansertib in combination with standard of care in the KRAS mutated mCRC setting through 2043 - SAN DIEGO, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced the United States Patent and Trademark Office (USPTO) has issued to Cardiff Oncology U.S. patent No. 12,144,813 with an expected expiration date of no earlier than 2043. The claims of the patent cover the method of using onvansertib in combination with bevacizumab (bev) for the treatment of KRAS mutated metastatic colorectal cancer (mCRC) patients who have
- Published positive Phase 2 trial results of onvansertib in combination with FOLFIRI and bev in second-line KRAS mutant mCRC in the peer-reviewed Journal of Clinical Oncology - - Initial data readout from first-line RAS-mutated mCRC randomized CRDF-004 trial expected by the end of 2024- - Projected runway with current cash resources into Q1 2026 - SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced financial results and recent highlights for the third quarter ended September 30, 2024. "This quarter has be
- Findings underscore that the combination of onvansertib with FOLFIRI and bevacizumab demonstrates clinical activity and is well tolerated in second-line KRAS-mutant mCRC - - Post hoc analysis resulted in a 7.7-fold higher clinical benefit in bev-naïve patients with an ORR of 77% compared to 10% in bev-exposed patients - - Results from this trial, along with translational studies, supported the transition of clinical development of onvansertib to first-line RAS-mutant mCRC - - Initial readout from first-line RAS-mutant mCRC CRDF-004 trial expected in H2 2024 - SAN DIEGO, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company lev
4 - Cardiff Oncology, Inc. (0001213037) (Issuer)
- Published positive Phase 2 trial results of onvansertib in combination with FOLFIRI and bev in second-line KRAS mutant mCRC in the peer-reviewed Journal of Clinical Oncology - - Initial data readout from first-line RAS-mutated mCRC randomized CRDF-004 trial expected by the end of 2024- - Projected runway with current cash resources into Q1 2026 - SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced financial results and recent highlights for the third quarter ended September 30, 2024. "This quarter has be
- Initial readout from first-line RAS-mut. mCRC randomized CRDF-004 trial expected in 2H 2024 - - Published preclinical data underscores the ability of onvansertib to overcome resistance to PARP inhibitors in high-grade serous ovarian carcinomas - - Five abstracts presented at AACR provide strong scientific rationale for the clinical development of onvansertib across multiple tumor types and various combinations - - Cash and equivalents of $60 million as of June 30, 2024, projected runway through the end of Q3 2025 - - Company will hold a conference call today at 4:30 p.m. ET/1:30 p.m. PT - SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-s
SAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that it plans to release financial results for the second quarter ended June 30, 2024 on Thursday, August 8 after the close of trading. Conference Call and Webcast Cardiff Oncology will host a conference call and live webcast at 4:30 p.m. ET/1:30 p.m. PT on August 8, 2024. Individuals interested in listening to the live conference call may do so by using the webcast link in the "Investors" section of the company's website at https://investors.cardiffoncology.com/news-event
First Patient Dosed in ONSEMBLE Phase 2 Randomized Trial of Onvansertib in Patients with KRAS/NRAS-mutated Metastatic Colorectal Cancer (mCRC) Introduced full membership of Scientific Advisory Board (SAB) Announced appointment of Fairooz Kabbinavar, MD, FACP, as Chief Medical Officer Cash, cash equivalents, and short-term investments of approximately $97 million as of March 31, 2023, projected runway into 2025 SAN DIEGO, May 4, 2023 /PRNewswire/ -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers, today announced financial results for the first-q
Brings world class capabilities and deep expertise in colorectal cancer and other solid tumor indications to advance the clinical development of onvansertib Served as the lead investigator for two practice-changing trials of bevacizumab (Avastin®) combinations leading to the approval of bevacizumab in metastatic colorectal cancer (mCRC)1,2 SAN DIEGO, Feb. 2, 2023 /PRNewswire/ -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers, today announced that it has strengthened its leadership team with the appointment of Fairooz Kabbinavar, MD, FACP, as
SAN DIEGO, Jan. 11, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage oncology company, developing new precision medicine treatment options for cancer patients in indications with the greatest unmet medical need including KRAS-mutated colorectal cancer, pancreatic cancer, and castrate-resistant prostate cancer, today announced the appointments of Tod Smeal, Ph.D., as chief scientific officer (CSO) and Charles Monahan, RPh, as senior vice president, regulatory affairs. "We are excited to welcome Tod and Charles to Cardiff Oncology as we approach key in
Craig Hallum initiated coverage of Cardiff Oncology with a rating of Buy and set a new price target of $8.00
HC Wainwright & Co. reiterated coverage of Cardiff Oncology with a rating of Buy and set a new price target of $25.00 from $26.00 previously
William Blair initiated coverage of Cardiff Oncology with a rating of Outperform
4 - Cardiff Oncology, Inc. (0001213037) (Issuer)
4 - Cardiff Oncology, Inc. (0001213037) (Issuer)
4 - Cardiff Oncology, Inc. (0001213037) (Issuer)
SC 13G/A - Cardiff Oncology, Inc. (0001213037) (Subject)
SC 13G/A - Cardiff Oncology, Inc. (0001213037) (Subject)
SC 13G - Cardiff Oncology, Inc. (0001213037) (Subject)